GLP-1 Drugs Reduce Opioid Use and Pain Codes in Fibromyalgia Patients by 35% | Research

The takeaway

In 96,050 matched fibromyalgia patients, GLP-1 receptor agonist use was associated with 35% reduced opioid prescriptions, 21% fewer pain codes, and 32% fewer fatigue codes over 5 years.

35% less opioid use
Fibromyalgia patients on GLP-1 drugs had significantly fewer opioid prescriptions over 5 years (OR 0.65)

What the researchers found

GLP-1RA use was associated with reduced opioid prescriptions (OR 0.65), pain diagnostic codes (OR 0.79), and fatigue codes (OR 0.68), all p<0.001, over 5-year follow-up in 96,050 matched fibromyalgia patients.

Why it matters

Fibromyalgia affects 2-4% of the population with no good treatments. A 35% reduction in opioid use is clinically significant and could reduce opioid dependence risk in this vulnerable population.

How the study worked

Retrospective propensity-matched cohort study using TriNetX (48,025 patients per group), with 5-year outcomes including opioid use, pain/fatigue/disability diagnostic codes, BMI, and HbA1c.

What this study cannot tell us

Retrospective observational design. Uses diagnostic codes as proxies for symptoms (not validated fibromyalgia outcome measures). BMI/HbA1c differences persisted despite matching.

How to read the evidence

Large propensity-matched observational study. Strong signal but needs RCT confirmation with validated fibromyalgia outcomes.

When this study was published

Published in 2025.

The bigger picture

This adds fibromyalgia to the growing list of conditions where GLP-1 drugs show unexpected benefits, likely through anti-inflammatory mechanisms or central pain modulation.

Questions still open

What mechanism explains GLP-1 drugs' apparent benefit in fibromyalgia?
Would GLP-1 drugs show benefit in a fibromyalgia-specific RCT with validated outcomes?
Is the reduced opioid use a direct analgesic effect or secondary to reduced pain?

Common questions

Could GLP-1 drugs help with fibromyalgia pain?

This large study found GLP-1 drug users with fibromyalgia had 21% fewer pain-related medical visits and 35% fewer opioid prescriptions over 5 years. While promising, clinical trials with validated pain measures are needed to confirm.

How might a diabetes drug reduce fibromyalgia symptoms?

The mechanism is unknown, but GLP-1 drugs have anti-inflammatory properties and affect brain circuits involved in pain processing. They may also reduce opioid use through central reward circuit modulation.

Read the original research

Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.

Rheumatology (Oxford, England), 65(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Eshak, Nouran; Irani, Anushka; Sullivan, Megan. (2026). Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.. Rheumatology (Oxford, England), 65(2). https://doi.org/10.1093/rheumatology/keag033